Quanterix Corp income statement
In fiscal 2025, Quanterix Corp reported revenue of $139m, up 1.1% on the year before, operating income of −$126m (a -90.4% margin) and net income of −$107m, or −$2.51 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18 | 23 | 38 | 57 | 86 | 111 | 106 | 122 | 137 | 139 | 153 |
| Cost of revenue | 10 | 13 | 20 | 30 | 38 | 46 | 60 | 48 | 54 | 74 | 88 |
| Gross profit | 8 | 10 | 18 | 27 | 48 | 65 | 45 | 74 | 83 | 65 | 65 |
| Research and development | 17 | 16 | 16 | 16 | 20 | 28 | 27 | 26 | 31 | 36 | 32 |
| Selling, general and administrative | 12 | 20 | 34 | 52 | 60 | 93 | 92 | 89 | 102 | 138 | 131 |
| Operating income | −22 | −26 | −32 | −42 | −32 | −57 | −104 | −46 | −53 | −126 | −153 |
| Net interest income | −1 | −1 | 0 | 1 | −0 | −0 | 5 | 16 | 15 | 9 | — |
| Provision for credit losses | — | — | — | — | 0 | 0 | 1 | 1 | 1 | 1 | 2 |
| Income before tax | −23 | −27 | −32 | −41 | −32 | −56 | −99 | −28 | −38 | −112 | −125 |
| Income tax | — | 0 | 0 | −0 | −0 | −0 | 0 | 1 | 0 | −5 | −2 |
| Net income | −23 | −27 | −32 | −41 | −32 | −56 | −100 | −28 | −39 | −107 | −123 |
| Diluted EPS | — | — | — | −$1.63 | −$1.07 | −$1.54 | −$2.69 | −$0.75 | −$1.00 | −$2.51 | −$2.63 |
| Diluted shares (average) | 2m | 4m | 22m | 25m | 30m | 36m | 37m | 38m | 38m | 43m | 47m |
| EBITDA | −21 | −26 | −30 | −39 | −27 | −52 | −99 | −40 | −46 | −110 | −129 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 36 | 35 | 30 | 24 | 40 | 44 | 36 | 33 |
| Cost of revenue | 16 | 13 | 15 | 14 | 23 | 24 | 21 | 20 |
| Gross profit | 20 | 22 | 15 | 10 | 17 | 20 | 16 | 13 |
| Research and development | 8 | 8 | 10 | 9 | 8 | 9 | 7 | 8 |
| Selling, general and administrative | 23 | 29 | 31 | 30 | 39 | 35 | 30 | 27 |
| Operating income | −12 | −15 | −26 | −37 | −37 | −25 | −41 | −49 |
| Net interest income | 4 | 3 | 3 | 3 | 1 | 1 | 1 | — |
| Provision for credit losses | 0 | −0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Income before tax | −8 | −12 | −23 | −30 | −36 | −23 | −18 | −49 |
| Income tax | 0 | −0 | −3 | −0 | −2 | 0 | −0 | −0 |
| Net income | −8 | −12 | −21 | −30 | −34 | −23 | −18 | −49 |
| Diluted EPS | −$0.22 | −$0.30 | −$0.53 | −$0.77 | −$0.73 | −$0.47 | −$0.37 | −$1.04 |
| EBITDA | −10 | −13 | −24 | −35 | −32 | −19 | −36 | −43 |
Compare with peers
- Pacific Biosciences Of California, Inc. income statement
- Grail, Inc. income statement
- Cryoport, Inc. income statement
- Cytek Biosciences, Inc. income statement
- Maravai Lifesciences Holdings, Inc. income statement
Head to head: PACB vs QTRXGRAL vs QTRXCYRX vs QTRX
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies